Medical AI Alliance
← Company Index
Pharma & CDMOKOSPI 102460304 approvals18 trials

REYON PHARMACEUTICAL CO., LTD

Official website

Founded in 1964 and listed on the KOSPI in 2010, Reyon Pharmaceutical sells the CT contrast agent Optiray and operates API and biologics CMO businesses.

As of 2026-10-10, REYON PHARMACEUTICAL CO., LTD has 304 Korean MFDS drug approvals, 1 PubMed-indexed paper on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Products & technology

  • OptirayCT contrast agent (original drug, exclusive domestic supply agreement with ISK)
  • Tacrolimusactive pharmaceutical ingredient
  • Teicoplaninactive pharmaceutical ingredient

Regulatory approvals

data.go.kr

304 Korean MFDS drug approvals · 1978–2026

  • MFDS drugOpticarpine Ophthalmic Solution 1%(single unit dose)2026-09-22
    Drug · Prescription · Approval202602857
  • MFDS drugDoneme Duo Tab. 10/20mg2026-08-06
    Drug · Prescription · Approval202602266
  • MFDS drugOptialpha Ophthalmic Solution 0.15%(single unit dose)2026-02-24
    Drug · Prescription · Approval202600549
  • MFDS drugPharmpain Relax Tab.2025-06-23
    Drug · OTC · Notification202501548
  • MFDS drugHyronsanonce Inj. (BDDE cross-linked sodium hyaluronate gel)(prefilled)2025-05-16
    Drug · Prescription · Approval202501209
  • MFDS drugTerazit Tab. 5mg2024-10-29
    Drug · Prescription · Approval202402552
  • MFDS drugThrombin Plus2024-07-31
    Drug · Prescription · Approval202401853
  • MFDS drugGinkgopet Tab. 240mg2024-07-01
    Drug · OTC · Notification202401598
  • MFDS drugNicechol Tab. 30mg2024-02-20
    Drug · Prescription · Approval202400360
  • MFDS drugCellon Ophthalmic Solution(Sodium Carboxymethylcellulose)(Single unit dose)2023-04-27
    Drug · OTC · Notification202301382
  • MFDS drugFODAGLE 5mg TAB(dapagliflozin propanediol monohydrate)2022-12-05
    Drug · Prescription · Approval202204351
  • MFDS drugPontmine Tab.2022-11-21
    Drug · OTC · Notification202204200
Show 68 more
  • MFDS drugPont-B Tab.2022-11-15
    Drug · OTC · Notification202204117
  • MFDS drugFodagle Tab. 10mg2022-05-30
    Drug · Prescription · Approval202202288
  • MFDS drugJairoMet Tablets 5/850mg2022-04-29
    Drug · Prescription · Approval202201744
  • MFDS drugJairoMet Tablets 5/500mg2022-04-29
    Drug · Prescription · Approval202201745
  • MFDS drugJairoMet Tablets 5/1000mg2022-04-29
    Drug · Prescription · Approval202201746
  • MFDS drugHepathistle 350 Soft Cap2022-04-13
    Drug · OTC · Notification202201549
  • MFDS drugDefoteli M SR tab 20/1000mg2022-04-04
    Drug · Prescription · Approval202201303
  • MFDS drugDefoteli M SR tab 10/750mg2022-04-04
    Drug · Prescription · Approval202201304
  • MFDS drugDefoteli M SR tab 10/500mg2022-04-04
    Drug · Prescription · Approval202201305
  • MFDS drugVerodion Injection2022-02-08
    Drug · Prescription · Approval202200587
  • MFDS drugDapasi Tab. 10/100mg2022-01-04
    Drug · Prescription · Approval202200045
  • MFDS drugEcoxia Tab.Revoked2021-03-25
    Drug · Prescription · Approval202102611
  • MFDS drugJairo Tablets 25mg(Empagliflozin)Revoked2021-03-12
    Drug · Prescription · Approval202102285
  • MFDS drugJairo Tablets 10mg(Empagliflozin)Revoked2021-03-12
    Drug · Prescription · Approval202102286
  • MFDS drugDefoteli Tab. 20mg2021-02-02
    Drug · Prescription · Approval202100997
  • MFDS drugOptipredi Eye Drops2021-01-14
    Drug · Prescription · Notification202100393
  • MFDS drugReyon Tofacitinib Tab. 5mgRevoked2021-01-14
    Drug · Prescription · Approval202100412
  • MFDS drugMiyurine Tab. 0.1mg2021-01-11
    Drug · Prescription · Approval202100309
  • MFDS drugMiyurine Tab. 0.2mg2021-01-11
    Drug · Prescription · Approval202100310
  • MFDS drugVastazet Tab 10/10mg2021-01-08
    Drug · Prescription · Approval202100189
  • MFDS drugVastazet Tab 10/20mg2021-01-08
    Drug · Prescription · Approval202100190
  • MFDS drugVastazet Tab 10/40mg2021-01-08
    Drug · Prescription · Approval202100191
  • MFDS drugBrozen Enteric Coated Tab. 45mg2020-07-14
    Drug · OTC · Notification202005052
  • MFDS drugForxuga Tab. 10mgRevoked2020-06-17
    Drug · Prescription · Approval202004450
  • MFDS drugLevoking Eye Drops 1.5%2020-05-29
    Drug · Prescription · Approval202004060
  • MFDS drugS-Vil Acet Soft Cap.Revoked2020-05-28
    Drug · OTC · Notification202004004
  • MFDS drugCeatin Cap.Revoked2020-05-26
    Drug · OTC · Notification202003875
  • MFDS drugFinaum Tab.2020-05-22
    Drug · Prescription · Approval202003757
  • MFDS drugDiqualon Ophthalmic Solution(Single unit dose)2020-05-15
    Drug · Prescription · Approval202003510
  • MFDS drugBonrent Inj.2020-04-29
    Drug · Prescription · Notification202003222
  • MFDS drugCefba Dry Syrup2020-04-29
    Drug · Prescription · Approval202003243
  • MFDS drugNewmetin Soft Cap.2020-04-28
    Drug · Prescription · Approval202003145
  • MFDS drugSapor SR Tab. 300mg2020-04-24
    Drug · Prescription · Approval202003031
  • MFDS drugCefba Tab.2020-04-23
    Drug · Prescription · Approval202002913
  • MFDS drugGanamoty SR Tab. 15mg2020-04-21
    Drug · Prescription · Approval202002825
  • MFDS drugGabentin Cap. 100mg2020-04-20
    Drug · Prescription · Approval202002758
  • MFDS drugTracom ER Semi Tab.2020-04-09
    Drug · Prescription · Approval202002519
  • MFDS drugMacpro Tab.2020-03-27
    Drug · Prescription · Approval202002142
  • MFDS drugCilover SR Cap. 100mg2020-03-05
    Drug · Prescription · Approval202001524
  • MFDS drugCilover SR Cap. 200mg2020-03-05
    Drug · Prescription · Approval202001525
  • MFDS drugMisartan Star Tab. 40/5mg2020-02-19
    Drug · Prescription · Approval202001161
  • MFDS drugMisartan Star Tab. 40/10mg2020-02-19
    Drug · Prescription · Approval202001162
  • MFDS drugMisartan Star Tab. 80/10mg2020-02-19
    Drug · Prescription · Approval202001164
  • MFDS drugMisartan Star Tab. 80/20mgRevoked2020-02-19
    Drug · Prescription · Approval202001158
  • MFDS drugMisartan Star Tab. 40/20mgRevoked2020-02-19
    Drug · Prescription · Approval202001163
  • MFDS drugMisartan Star Tab. 80/5mgRevoked2020-02-19
    Drug · Prescription · Approval202001165
  • MFDS drugCenat Tab.2020-02-18
    Drug · Prescription · Approval202001094
  • MFDS drugAstylene Tab.2020-02-14
    Drug · Prescription · Notification202000966
  • MFDS drugNewmetin Mini Soft Cap.2020-01-31
    Drug · Prescription · Approval202000515
  • MFDS drugBerry-F Tab.Revoked2020-01-10
    Drug · OTC · Notification202000177
  • MFDS drugCavedil Tab. 12.5mg2019-12-16
    Drug · Prescription · Approval201908436
  • MFDS drugIrosta Tab. 5mg2019-11-26
    Drug · Prescription · Approval201908080
  • MFDS drugLaylbon Tab.2019-11-20
    Drug · Prescription · Notification201908018
  • MFDS drugReyon Cifloxacin Inj.2019-10-31
    Drug · Prescription · Notification201907594
  • MFDS drugEperisin SR Tab.2019-10-31
    Drug · Prescription · Approval201907606
  • MFDS drugReyon Rasagiline Mesylate Tab.Revoked2019-10-31
    Drug · Prescription · Approval201907650
  • MFDS drugReyon Rasagiline Mesylate Tab. 0.5mgRevoked2019-10-31
    Drug · Prescription · Approval201907651
  • MFDS drugMontelienchew Tab. 5mg2019-10-04
    Drug · Prescription · Approval201907082
  • MFDS drugMontelienchew Tab. 4mg2019-09-26
    Drug · Prescription · Approval201906876
  • MFDS drugPharmpain Pro Soft Cap.2019-08-26
    Drug · OTC · Notification201906058
  • MFDS drugPharmpain Ibu Soft Cap.2019-08-26
    Drug · OTC · Notification201906059
  • MFDS drugDecbfen Tab. 300mg2019-08-19
    Drug · OTC · Notification201905840
  • MFDS drugMontelien Tab. 10mg2019-07-16
    Drug · Prescription · Approval201904764
  • MFDS drugLatofu Tab.2019-06-26
    Drug · Prescription · Approval201904378
  • MFDS drugEsbet Tab. 20mg2019-06-05
    Drug · Prescription · Approval201903752
  • MFDS drugEsbet Tab. 40mg2019-06-05
    Drug · Prescription · Approval201903753
  • MFDS drugTediad Tab.Revoked2019-06-05
    Drug · Prescription · Approval201903751
  • MFDS drugItomoty Tab.2019-05-31
    Drug · Prescription · Approval201903633

Showing the 80 most recent of 304 records.

Clinical trials

data.go.kr

18 MFDS clinical trial authorisations · 2013–2025 (Bioequivalence 16 · Phase 1 2)

  • Phase 1RYILT2-T2025-12-09

    2 trial sites

  • Phase 1RYILT2-T2025-12-08

    2 trial sites

  • Bioequivalence아크로정(아세클로페낙)2024-11-01

    2 trial sites

  • Bioequivalence레바진정(레바미피드)2024-10-22

    2 trial sites

  • BioequivalenceRYRDT-T2023-04-20

    2 trial sites

  • BioequivalenceRYRDT-T2023-04-17

    2 trial sites

  • Bioequivalence이연클로피도그렐황산수소염정2021-07-22

    2 trial sites

  • Bioequivalence이록펜정(록소프로펜나트륨)2021-05-20

    2 trial sites

  • Bioequivalence바스타틴정20밀리그램(아토르바스타틴칼슘삼수화물)2020-12-09

    1 trial site

  • Bioequivalence가벤틴캡슐300mg(가바펜틴)2020-08-11

    2 trial sites

  • Bioequivalence가나모티정(모사프리드시트르산염수화물)2020-07-09

    1 trial site

  • Bioequivalence플루코정150밀리그램(플루코나졸)2019-09-30

    2 trial sites

Show 6 more
  • Bioequivalence플로리스정75mg(나프토피딜)(가칭)2017-10-27

    2 trial sites

  • Bioequivalence이연콜키신정0.6밀리그램(콜키신)(가칭)2015-10-23

    2 trial sites

  • Bioequivalence리큐버정1밀리그램(엔테카비르)2014-12-24

    2 trial sites

  • Bioequivalence엠디비카정5/20밀리그램2014-07-09

    2 trial sites

  • Bioequivalence이로스타정(로수바스타틴칼슘)2014-01-16

    2 trial sites

  • Bioequivalence리목스정400mg(목시플록사신염산염)2013-10-29

    2 trial sites

Global clinical trials

ClinicalTrials.gov · sponsor-matched

R&D and key agreements

Source: DART corporate disclosure

RY104(NG101) · 노인성 황반변성(AMD) · Targets age-related macular degeneration; the market was about USD 10.46 billion in 2024 and is projected to grow at a 10.7% CAGR to about USD 17.37 billion by 2029.

RY110(TB-100) · 고형암 · 비임상시험(안전성-GLP Tox) · An NK-cell biologic that selectively recognizes ligands on cancer-affected abnormal cells to induce cell death, using a proprietary platform that produces NK cells from a single iPSC line. Currently preparing to enter domestic clinical trials; competing developers include Fate Therapeutics, Nkarta, Affimed NV, ImmunityBio, Anthrogenesis, and Artiva Biotherapeutics. The global solid-tumor drug market was about USD 210.4 billion in 2024, projected to reach about USD 408.4 billion by 2033.

RY108 · 진균 감염증 · A chemical new drug that binds specifically to fungi and inhibits the intracellular signaling molecule calcineurin, designed for selective antifungal effect with reduced immunosuppression.

Key disclosures

KRX KIND via OpenDART

Publications

PubMed · affiliation-matched

Patents

KIPRIS · applicant-matched
Show 36 more patents

AI reads

MAA server logs · IP-verified
71
Times AI engines pulled REYON PHARMACEUTICAL CO., LTD's records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

1
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

70
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

11
live 0
Last 7 days
57
live 1
Last 30 days
71
live 1
All time
  • OpenAIChatGPT-Userlive1
  • OpenAIOAI-SearchBot64
  • PerplexityPerplexityBot2
  • AnthropicClaudeBot2
  • MicrosoftBingbot1
  • GoogleGoogleOther1

Measured since Aug 27, 2026 · 5 AI engines · last read Oct 9, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for REYON PHARMACEUTICAL CO., LTD and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview. Send us materials and we will add them

Companies in the same categoryPharma & CDMO

ILDONG HOLDINGS CO.,LTD100

Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.

Yuyu Pharma, Inc.100

Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.

IL DONG PHARMACEUTICAL CO., LTD.100

Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.

Medy-Tox Inc.99

Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.

GC Biopharma Corp.97

KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.

DAEWON PHARMACEUTICAL CO.,LTD85

KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.

SAMSUNG BIOLOGICS CO.,LTD.85

Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.

GENOLUTION INC.85

Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.

AHN-GOOK PHARMACEUTICAL Co., Ltd.85

Ahn-Gook Pharmaceutical sells the cough/expectorant drug Sinecuran and the eye-health supplement Tobicom.

CORESTEMCHEMON Inc.85

Founded in 2003 and listed on KOSDAQ in 2015, Corestem Chemon develops stem cell therapies and provides nonclinical CRO services, including the ALS treatment Neuronata-R.

BIO-FD&C CO.,LTD.85

Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.

HANDOK Inc.85

KOSPI-listed comprehensive pharma company behind Amaryl diabetes drug and the USD 86.25M HL5101 anticancer out-license deal.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition